A clinical trial to study the effects of preoperative use of Tapentadol 75mg for postoperative pain relief in laparoscopic cholecystectomy

Evaluating the pre-emptive role of Tapentadol 75 mg for attenuation of postoperative pain after laparoscopic cholecystectomy

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2014/05/004621

Enrollment

Registered

2014-05-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Age between 18 and 60 yrs, ASA I & II, Both male and female, Patients undergoing lap cholecystectomy

Interventions

Intervention1: Tab Tapentadol 75mg: Tab Tapentadol 75mg (DOL PROXYVON WOCKHARDT TARUS Pharmaceutical ltd)given 2 hours before surgery with sips of water. Control Intervention1: Tab Ranitidine hydroch

Eligibility

Inclusion criteria

Inclusion criteria: patients aged between 18 to 60 yrs with ASA I & II, Of either sex, undergoing lap cholecystectomy were included

Exclusion criteria

Exclusion criteria: Pt with impaired kidney or liver functions, H/o drug or alcohol abuse, H/o chr pain or daily intake of analgesic, Uncontrolled medical disease (DM & HTN), H/o intake of NSAID within 24 h of surgery,

Design outcomes

Primary

Measure	Time frame
Total analgesic requirement Timepoint: 24hr postoperatively.	—

Secondary

Measure	Time frame
time of first analgesic requirement, incidence of postoperative pain in terms of VAS score and side effects if any.Timepoint: incidence of postoperative pain in terms of VAS score at 0, 2,4,8,12 and 24hr postoperatively and side effects if any during 24hr postoperatively.	—

Countries

India

Contacts

Public ContactDr Ghanshyam Yadav

Institute of Medical Sciences, Banaras Hindu University

ghanshyamx@rediffmail.com919838894169

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026